Elbasvir
Elbasvir[edit]
Elbasvir is an antiviral drug used in the treatment of hepatitis C. It is a direct-acting antiviral (DAA) agent that targets the nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV). Elbasvir is commonly used in combination with other antiviral medications to enhance its efficacy in clearing the virus from the body.
Mechanism of Action[edit]
Elbasvir works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. By blocking this protein, elbasvir disrupts the viral replication process, thereby reducing the viral load in the patient's body. This action helps in achieving a sustained virologic response (SVR), which is considered a cure for hepatitis C.
Clinical Use[edit]
Elbasvir is primarily used in combination with grazoprevir, another antiviral agent, to treat chronic hepatitis C infection. This combination is effective against multiple genotypes of the virus, particularly genotypes 1 and 4. The treatment regimen and duration depend on the genotype of the virus and the presence of any resistance-associated substitutions (RASs).
Side Effects[edit]
Common side effects of elbasvir include fatigue, headache, nausea, and insomnia. Patients may also experience elevated liver enzymes, which should be monitored during treatment. Serious side effects are rare but can include severe liver problems, especially in patients with advanced liver disease.
Drug Interactions[edit]
Elbasvir can interact with other medications, potentially affecting their efficacy or increasing the risk of adverse effects. It is important to review all medications a patient is taking before starting treatment with elbasvir. Notable interactions include those with certain anticonvulsants, antiretrovirals, and statins.
